Jenny McGovern

Company: Quell Therapeutics

Job title: Director Non-Clinical Group Leader

Seminars:

Developing Safe & Efficacious Cellular Therapies For Autoimmune Disease: How Do We Ensure An Acceptable Risk-Benefit Profile? 1:00 pm

CAR-T and other cellular therapies have had huge success in the treatment of hematological malignancies; however, adverse events (AEs) including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been observed. For patients with cancer, where mortality is a real concern, these AEs are often considered an acceptable risk in the search…Read more

day: Pre-Conference Day